Cambridge, UK and Newcastle, UK, 18th February 2026: Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, today announced that it has acquired the ophthalmology business Read More